Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH LES FEUGRAIS CHI ELBEUF
BP 310, 76503 ELBEUF CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Neurology · 2014
International journal of stroke : official journal of the International Stroke Society · 2010
Rationale Oxidative stress is a major contributor to brain damage in patients with ischaemic stroke. Uric acid (UA) is a potent endogenous antioxidant molecule. In experimental ischaemia in rats, the exogenous administration of uric acid is neuroprotective and enhances the effect of rtPA. Moreover, in acute stroke patients receiving rtPA within 3 h of stroke onset, the intravenous administration of uric acid is safe, prevents an early decline in uric acid levels and reduces an early increase in oxidative stress markers and in active matrix metalloproteinase nine levels. Aim To determine whether the combined treatment with uric acid and rtPA is superior to rtPA alone in terms of clinical efficacy in acute ischaemic stroke patients treated within the first 4.5 h of onset of symptoms. Study design Multicentre, interventional, randomised, double-blind and vehicle-controlled efficacy study with parallel assignment (1:1). Estimated enrolment: 420 patients over 3 years, starting in January 2010. Treatment arms included patients will receive a single intravenous infusion of 1 g of UA dissolved in a vehicle (500 ml of 0.1% lithium carbonate and 5% mannitol) ( n = 210) or vehicle alone ( n = 210). Inclusion and exclusion criteria: the study will include patients older than 18 years, treated with rtPA within the first 4.5 h of clinical onset and with a baseline National Institute of Health Stroke Scale score >6 and <25 and a modified Rankin Scale score ≤ 2 before the ischaemic event. Patients with renal insufficiency, gout or asymptomatic hiperuricaemia treated with allopurinol will be excluded. Study outcomes The primary outcome measure is the proportion of patients achieving an modified Rankin Scale of 0 to 1 at 3 months after treatment or two in those patients with a prior qualifying modified Rankin Scale of 2. Secondary outcome measures include the final infarction volume measured at 72 h and the proportion of patients with symptomatic intracranial haemorrhage (≥ 4 points of increase in the National Institute of Health Stroke Scale score).
Clinical chemistry and laboratory medicine · 2012
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
HIV research & clinical practice · 2020 · Journal Article
Vizcarra P, Gallego J, Vivancos MJ, Sifuentes WA, et al.
International journal of stroke : official journal of the International Stroke Society · 2010 · Journal Article
Amaro S, Cánovas D, Castellanos M, Gállego J, et al.
Revista espanola de anestesiologia y reanimacion · 2008 · Case Reports
Echeverri M, Ferrer P, Gallego J, Abengoechea A
Medicina clinica · 1980 · Journal Article
Sanz Guajardo D, Barbolla ML, Fernández Fernández J, Gallego JL, et al.
Actas dermo-sifiliograficas · 1979 · Case Reports
Vives P, Hernanz JM, García Almagro D, Gallego JR, et al.
International journal of spine surgery · 2020 · Journal Article
Alvarez-Galovich L, Tome-Bermejo F, Moya AB, Mahillo-Fernandez I, et al.
The Lancet. Neurology · 2014 · Clinical Trial, Phase II
Chamorro A, Amaro S, Castellanos M, Segura T, et al.
Rheumatology international · 2023 · Observational Study
Alle G, Scolnik M, Scaglioni V, Gallego JFJ, et al.
The European respiratory journal · 1994 · Case Reports
Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, Gomez ML, et al.
Clinical chemistry and laboratory medicine · 2012 · Evaluation Study
Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, et al.
Medicina clinica · 2021 · Case Reports
Vizcarra P, Gallego J, Sobrino C, Sifuentes WA, et al.
The Lancet. Neurology · 2014 · Clinical Trial, Phase II
Chamorro A, Amaro S, Castellanos M, Segura T, et al.
International journal of spine surgery · 2020 · Journal Article
Alvarez-Galovich L, Tome-Bermejo F, Moya AB, Mahillo-Fernandez I, et al.